In the past decade, artificial intelligence (AI) has slowly seeped into medicine, promising to revolutionize diagnostics, treatment planning, and patient management. But for all the hype, one major barrier has remained: cost. That’s now changing.
Enter DeepSeek, a Chinese AI company that has managed to train models rivaling OpenAI’s GPT-4 for a fraction of the cost. Their efficiency isn’t just a technical achievement. It’s a tectonic shift in how AI will be developed and deployed across industries, including eye care.
The core takeaway? The cost of intelligence is dropping, and that means more AI, more competition, and ultimately, better outcomes for patients.
AI Is Getting Cheaper. What Does That Mean for Eye Care?
Eye care has been one of the earliest adopters of AI in medicine. From retinal screening algorithms for diabetic retinopathy to AI-powered OCT analysis for macular degeneration, the potential for automation and augmentation has been clear.
Now, as AI development costs plummet, we are poised for a wave of new entrants into the field. Instead of just a few AI-driven diagnostic platforms, we could see dozens, if not hundreds, of startups competing to create more precise, accessible, and cost-effective solutions for the optical, optometric, and ophthalmic industry.
This increased competition will drive:
- More affordable AI tools: Lower costs mean that AI-driven diagnostics will no longer be confined to large groups or chains. Independent clinics and optometry offices could soon have powerful and affordable AI at their fingertips.
- Faster innovation cycles: The pace of progress and competition will accelerate improvements in administrative, operational, and diagnostic AI.
- Global accessibility: One of AI’s greatest promises in eye care is its ability to bridge the global shortage of ophthalmologists. More competition means lower deployment costs, making AI tools viable for clinics in low-resource settings.
- Explainability and Trust: With more advanced reasoning capabilities, will AI finally help us break through the black box problem? AI in eye care operates across three fundamental levels: as an assistant (think scribe), as an agent (think your specific avatar explaining your specific surgery and answering questions just like you), or as a superpower. The superpower use cases — such as predicting neurodegenerative diseases from retinal images — often struggle with explainability. Advanced AI reasoning, driven by models such as DeepSeek, may push us closer to making these decisions more interpretable, transparent, and clinically actionable.
What’s Next? A Future of AI-Driven Eye Care
The falling cost of AI development is a huge win for patients.
In five years, I predict that AI in eye care will be standard of care. Whether it’s your AI assistant streamlining workflows or a diagnostic AI solution aiding in disease detection, we’ll see an explosion of intelligent tools that lower costs, improve outcomes, and enhance how we deliver care.
However, not all AI applications will evolve at the same pace. Administrative AI will take off faster than diagnostic AI, primarily because it’s the lower-hanging fruit with fewer payor and regulatory hurdles and clearer financial incentives.
The bottom line? AI in eye care is about to get a whole lot smarter, cheaper, and more competitive.
Author
